

Henry Schein Enters Exclusive Distribution Agreement with CytoChip

2026-01-06

Company to Offer CLIA-Waived Hematology Analyzer to U.S. Customers

MELVILLE, N.Y., January 6, 2026 — Henry Schein, Inc. (Nasdaq: HSIC) entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC[®] system, a 510(k) cleared device. Available now to Henry Schein customers in the United States, this solution is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA waiver status from the U.S. Food and Drug Administration (FDA), a designation that helps expand access to accurate, lab-quality hematology testing at the point of care.

“We are pleased to join with CytoChip to provide the CitoCBC System to our customers, helping to bring essential lab testing out of the hospital and into the office, with results provided to the patient during their visit,” said Ty Ford, Vice President and General Manager of Sales for Henry Schein Medical. “This collaboration strengthens our commitment to offering health care providers products and solutions that increase efficiencies while enhancing patient care.”

The CitoCBC system offers:

- **Fast Results:** Delivering full test results in eight minutes.
- **Ease of Use:** Requiring minimal staff training.
- **Small Sample:** Using blood collected in a venous draw tube to analyze 16 parameters of the blood cells, including all five types of white blood cells.
- **Lab-Quality Accuracy:** Miniaturizing advanced lab technology (fluorescent flow cytometry) onto a small “Chip,” CitoCBC provides the result accuracy expected from a central laboratory, but on a countertop device.

“Partnering with Henry Schein enables us to expand the reach of CitoCBC, assisting health care providers in places like physician offices, urgent care centers, and even pharmacies, to get immediate diagnostic data,” said Dr. Wendian Shi, CEO of CytoChip. “Together, we can help make diagnostic decisions more informed than ever before – improving patients’ access to care.”

Henry Schein’s exclusivity in the U.S. includes ambulatory care settings such as physician offices, urgent care centers, and more, as well as critical access hospitals with 25 patient beds or fewer. It does not include long-term care or acute care facilities.

“For patients, point-of-care testing can transform waiting into knowing, enabling faster treatment and helping improve outcomes. For providers, it can offer real-time insights, helping to eliminate diagnostic delays and optimize use of resources,” said Gary Dennis, Senior Director of Laboratory Services for Henry Schein Medical. “The CitoCBC system is a perfect example of the importance of this technology.”

For more product information, please visit <https://www.henryschein.com/citocbc>.

*The CitoCBC[®] system is not indicated for use in diagnosing or monitoring of oncology patients, critically ill patients, or children under the age of 2 years.

About CytoChip Inc.

CytoChip Inc. is a diagnostic technology company founded in 2016 by researchers from Caltech and other leading institutions. Headquartered in Irvine, CA, the company is dedicated to assisting healthcare providers in delivering rapid, data-driven diagnostics and expanding patients' access to care, through innovations in microfluidics and data analytics.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 **Team Schein Members** worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based **dental** and **medical** practitioners work more efficiently so they can provide quality care more effectively. These solutions also support **dental laboratories, government and institutional health care clinics**, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers.

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company's sales reached \$12.7 billion in 2024 and have grown at a compound annual rate of approximately 11.2 percent since Henry Schein became a public company in 1995.

For more information, visit Henry

Schein at www.henryschein.com, [Facebook.com/HenrySchein](https://www.facebook.com/HenrySchein), [Instagram.com/HenrySchein](https://www.instagram.com/HenrySchein), [LinkedIn.com/Company/HenrySchein](https://www.linkedin.com/company/HenrySchein), and [@HenrySchein](https://twitter.com/HenrySchein) on X.

HS-M

CONTACT:

Lauren DelGuidice

Associate Manager, Corporate Media Relations, Henry Schein, Inc.

Lauren.DelGuidice@henryschein.com

631.479.7309

###